Sofinnova Partners, a European life sciences venture capital firm based in Paris, London, and Milan, closed its Digital Medicine Fund, at $200M.
Led by Partners Edward Kliphuis, and Simon Turner, the fund targets three main areas: enabling technologies, analytics, and treatment. It provides entrepreneurs with financial backing, expertise, and deeply-rooted healthcare networks, empowering them to address global healthcare challenges and enhance patient outcomes worldwide.
The two most recent additions to the Sofinnova Digital Medicine portfolio included:
– L’école AI, creator of a “machine teaching” technology and established by an ex-Twitter Cortex founding team member, simplifies the deployment of deep-learning systems for computer vision in life sciences applications.
– Betteromics, the “Omics AI Cloud,” unifies disparate health and omics data into a single source of truth through a certified SaaS platform, backed by the expertise of its founding team from GRAIL, Verily and Google’s Search Knowledge Graph.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. The firm is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage, and actively partners with entrepreneurs as a lead or cornerstone investor to develop transformative innovations.
FinSMEs
26/10/2023